<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416296</url>
  </required_header>
  <id_info>
    <org_study_id>placenta</org_study_id>
    <nct_id>NCT03416296</nct_id>
  </id_info>
  <brief_title>Role of Ultrasound in Diagnosis of Placenta Previa and MAP</brief_title>
  <official_title>Evaluation of Role of Ultrasound TA,TV,TP in Diagnosis of Placenta Previa and MAP(Morbidly Adherent Placenta )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Center, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta accreta occurs when the placental implantation is abnormal. The marked rise in
      incidence has been assumed the increasing prevalence of cesarean delivery in recent years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most accepted theory is that abnormal placentation . The most important risk factor for
      placenta accreta is placenta previa after a prior cesarean delivery. The first clinical
      manifestation of placenta accreta is usually severe , life-threatening hemorrhage. The
      recommended intervention of suspected placenta accreta is planned preterm cesarean
      hysterectomy with the placenta left in situ.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants who will be diagnosed to have normal placenta or placenta previa or morbidly adherent placenta by US</measure>
    <time_frame>within 6 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Morbidly Adherent Placenta</condition>
  <arm_group>
    <arm_group_label>normal placenta</arm_group_label>
    <description>TA , TV ,TP us</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placenta previa and MAP</arm_group_label>
    <description>TA,TV.TP us</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      uterus in case of hysterectomy after cesarean hysterectomy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant females with previous cs will be subjected to US to assess placental location and
        MAP
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant ladies with previous cesarean sections

          -  GA above 34 weeks

        Exclusion Criteria:

          -  Primigravida patients

          -  GA below 34 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant females with GA above 34 weeks</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Alalfy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Elgazzar</last_name>
    <phone>01014005959</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Algazeerah</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Alalfy, master</last_name>
      <phone>+201002611058</phone>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elgazzar, M.D</last_name>
      <phone>+201014005959</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Alalfy, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aljazeera Hospital</investigator_affiliation>
    <investigator_full_name>Mahmoud Alalfy</investigator_full_name>
    <investigator_title>Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

